Skip to content
2000
Volume 6, Issue 3
  • ISSN: 2666-7967
  • E-ISSN: 2666-7975

Abstract

Introduction

To evaluate the efficacy and safety of Plasma Exchange (PE) in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) positive pneumonia patients.

Methods

This study was a case series conducted at a referral hospital. Twenty SARS-CoV-2-positive patients had an oxygen saturation of 80-90%, and the respiratory rate above 30 per minute. These symptoms started 1 week after the onset of the disease. All patients had less than 90% oxygen saturation and needed respiratory support (oxygen therapy) treated with plasma exchange on 3-5 consecutive days during hospitalization. We followed the amount of oxygen saturation, which was in the form of increasing the patient's oxygen saturation above 90% without oxygen supply and above 92% without oxygen, improving shortness of breath and improving patients' clinical symptoms.

Results

Our study included a total of 20 COVID-19 patients with an overall mean age of 48.9 ± 12.1 years (range: 39-58 years); 60% (n=12) were males, 34.5% of whom benefited from Therapeutic plasma exchange (TPE) sessions. On the third day after the treatment, shortness of breath improved in these patients. Oxygen saturation in all twenty patients increased after the procedure of plasma exchange. Clinical symptoms of all patients were decreasing shortness of breath and improving patients' clinical symptoms after the procedure.

Conclusion

According to our observations, plasma exchange could not show a significant therapeutic effect in COVID-19 patients with severe lung involvement.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975274661240614051821
2024-06-24
2025-09-27

  • From This Site

    /content/journals/covid/10.2174/0126667975274661240614051821
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ZhuN. ZhangD. WangW. A novel coronavirus from patients with pneumonia in China, 2019.N. Engl. J. Med.2020382872773310.1056/NEJMoa2001017 31978945
     [Google Scholar]
  2. Center for Systems Science and EngineeringCoronavirus COVID-19 global cases.Available from: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/ 2019
  3. HolshueM.L. DeBoltC. LindquistS. The first case of the 2019 novel coronavirus in the United States.N. Engl. J. Med.20203821092993610.1056/NEJMoa2001191 32004427
     [Google Scholar]
  4. MubarakM. NasriH. COVID-19 nephropathy; an emerging condition caused by novel coronavirus infection.J. Nephropathol.202093e2110.34172/jnp.2020.21
     [Google Scholar]
  5. ValizadehR. BaradaranA. MirzazadehA. BhaskarL.V.K.S. Coronavirus-nephropathy; renal involvement in COVID-19.J. Renal Inj. Prev.202092e1810.34172/jrip.2020.18
     [Google Scholar]
  6. ValizadehR. DadashzadehN. ZakeriR. KellnerJ.S. RahimiM.M. Drug therapy in hospitalized patients with very severe symptoms following COVID-19.J. Nephropharmacol.202092e2110.34172/npj.2020.21
     [Google Scholar]
  7. DadashzadehN. FarshidS. ValizadehR. NanbakhshM. RahimiM.M. Acute respiratory distress syndrome in COVId-19 disease.Immunopathol Persa202062e16
     [Google Scholar]
  8. Coronavirus (COVID-19) | Drugs.Available from: https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-COVID-19-drugs
  9. SinghV. JainS.K. MishraV. A recent update on SARS-CoV-2 transmission and its variants: Transmission, pathogenic mechanism, and treatment.Coronaviruses2023412023
     [Google Scholar]
  10. VabreN. BrittonG.J. GruberC. Immunology of COVID-19: Current state of the science.Immunity202052910914
     [Google Scholar]
  11. PachecoL.M. SilvaP.L. CruzF.F. Pathogenesis of multiple organ injury in COVID-19 and potential therapeutic strategies.Front. Physiol.20211259322310.3389/fphys.2021.593223 33584343
     [Google Scholar]
  12. YangL. LiuS. LiuJ. COVID-19: Immunopathogenesis and Immunotherapeutics.Signal Transduct. Target. Ther.20205112810.1038/s41392‑020‑00243‑2 32712629
     [Google Scholar]
  13. LiL. ZhangW. HuY. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial.JAMA2020324546047010.1001/jama.2020.10044 32492084
     [Google Scholar]
  14. LiuS.T.H. LinH.M. BaineI. Convalescent plasma treatment of severe COVID-19: A propensity score–matched control study.Nat. Med.202026111708171310.1038/s41591‑020‑1088‑9 32934372
     [Google Scholar]
  15. KhamisF. Al-ZakwaniI. Al HashmiS. Therapeutic plasma exchange in adults with severe COVID-19 infection.Int. J. Infect. Dis.20209921421810.1016/j.ijid.2020.06.064 32585284
     [Google Scholar]
  16. ShiH. ZhouC. HeP. Successful treatment with plasma exchange followed by intravenous immunoglobulin in a critically ill patient with COVID-19.Int. J. Antimicrob. Agents202056210597410.1016/j.ijantimicag.2020.105974 32298745
     [Google Scholar]
  17. ZhangL. ZhaiH. MaS. ChenJ. GaoY. Efficacy of therapeutic plasma exchange in severe COVID-19 patients.Br. J. Haematol.20201904e181e18310.1111/bjh.16890 32453903
     [Google Scholar]
  18. AnnaneD. BellissantE. CavaillonJ.M. Septic shock.Lancet20053659453637810.1016/S0140‑6736(04)17667‑8 15639681
     [Google Scholar]
  19. VincentJ.L. JonesG. DavidS. OlariuE. CadwellK.K. Frequency and mortality of septic shock in Europe and North America: A systematic review and meta-analysis.Crit. Care201923119610.1186/s13054‑019‑2478‑6 31151462
     [Google Scholar]
  20. RackowE.C. AstizM.E. Pathophysiology and treatment of septic shock.JAMA1991266454855410.1001/jama.1991.03470040112032 2061983
     [Google Scholar]
  21. BulentG. HakanK. IbrahimS. UlkemC. LutfiT. COVID-19 study group. Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: A retrospective study.Crit. Care2020241492
     [Google Scholar]
  22. BalagholiS. DabbaghiR. EshghiP. MousaviS.A. HeshmatiF. MohammadiS. Potential of therapeutic plasmapheresis in treatment of COVID-19 Patients: Immunopathogenesis and Coagulopathy.Ann. Med. Surg.202171102920
     [Google Scholar]
  23. LiH. LiuS.M. YuX.H. TangS.L. TangC.K. Coronavirus disease 2019 (COVID-19): Current status and future perspectives.Int. J. Antimicrob. Agents202055510595110.1016/j.ijantimicag.2020.105951 32234466
     [Google Scholar]
  24. VardanjaniE.A. RoncoC. RafieiH. GolitalebM. PishvaeiM.H. MohammadiM. Early hemoperfusion for cytokine removal may contribute to the prevention of intubation in patients infected with COVID-19.Blood Purif.202150225726010.1159/000509107 32594085
     [Google Scholar]
  25. HashemianS.M. ShafighN. AfzalG. Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS).Pulmonology202127648649210.1016/j.pulmoe.2020.10.017 33358260
     [Google Scholar]
  26. DastanF. SaffaeiA. MortazaviS.M. Continues renal replacement therapy (CRRT) with disposable hemoperfusion cartridge: A promising option for severe COVID-19.J. Glob. Antimicrob. Resist.20202134034110.1016/j.jgar.2020.04.024 32353526
     [Google Scholar]
  27. ArulkumaranN. ThomasM. BrealeyD. Plasma exchange for COVID-19 thrombo-inflammatory disease.eJHaem202121263210.1002/jha2.140 33363289
     [Google Scholar]
  28. FernandezJ. GinèsG.J. OlivasP. Plasma exchange: An effective rescue therapy in critically ill patients with coronavirus disease 2019 infection.Crit. Care Med.20204812e1350e135510.1097/CCM.0000000000004613 32833695
     [Google Scholar]
  29. GluckW.L. CallahanS.P. BrevettaR.A. Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19.Respir. Med.202017510618810.1016/j.rmed.2020.106188 33190086
     [Google Scholar]
  30. MorathC. WeigandM.A. ZeierM. SpeerC. HecklerT.S. MerleU. Plasma exchange in critically ill COVID-19 patients.Crit. Care202024148110.1186/s13054‑020‑03171‑3 32753056
     [Google Scholar]
  31. MoradiH. AbbasiS. Hemoperfusion as a supportive treatment in a COVID-19 patient with late pulmonary thromboembolism: A case report.Int. Med. Case Rep. J.20201334134510.2147/IMCRJ.S263127 32821175
     [Google Scholar]
  32. CegolonL. EinollahiB. PanahiY. On therapeutic plasma exchange against severe COVID-19-associated pneumonia: An observational clinical study.Front. Nutr.2022980982310.3389/fnut.2022.809823 35308291
     [Google Scholar]
  33. KeithP.D. WellsA.H. HodgesJ. FastS.H. AdamsA. ScottL.K. The therapeutic efficacy of adjunct therapeutic plasma exchange for septic shock with multiple organ failure: A single-center experience.Crit. Care202024151810.1186/s13054‑020‑03241‑6 32831133
     [Google Scholar]
  34. BouayedM.Z. LaaribiI. BenainiI. Therapeutic plasma exchange in the treatment of COVID-19 induced cytokine storm: The first Moroccan experience.BMC Infect. Dis.2023231829
     [Google Scholar]
  35. WanS. XiangY. FangW. Clinical features and treatment of COVID-19 patients in northeast Chongqing.J. Med. Virol.202092779780610.1002/jmv.25783 32198776
     [Google Scholar]
  36. CegolonL. JavanbakhtM. MastrangeloG. Nasal disinfection for the prevention and control of COVID-19: A scoping review on potential chemo-preventive agents.Int. J. Hyg. Environ. Health202023011360510.1016/j.ijheh.2020.113605 32898838
     [Google Scholar]
  37. CarsanaL. SonzogniA. NasrA. Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy.Lancet Infect. Dis.2020201135114010.1016/S1473‑3099(20)30434‑5 32526193
     [Google Scholar]
  38. TurgutkayaA. Yavaşoğluİ. BolamanZ. Application of plasmapheresis for Covid-19 patients.Ther. Apher. Dial.202125224824910.1111/1744‑9987.13536 32510799
     [Google Scholar]
  39. JoseR.J. ManuelA. COVID-19 cytokine storm: The interplay between inflammation and coagulation.Lancet Respir. Med.202086e46e4710.1016/S2213‑2600(20)30216‑2 32353251
     [Google Scholar]
  40. YiğenoğluT.N. UlasT. DalM.S. KorkmazS. ErkurtM.A. AltuntaşF. Extracorporeal blood purification treatment options for COVID-19: The role of immunoadsorption.Transfus. Apheresis Sci.202059410285510.1016/j.transci.2020.102855 32636114
     [Google Scholar]
  41. COVID-19 Treatment Guidelines PanelCoronavirus Disease. https://www.COVID19treatmentguidelines.nih.gov/ 2019
  42. FoxT. Plasmapheresis to remove amyloid fibrin(ogen) particles for treating the post-COVID-19 condition.Cochrane Database Syst. Rev.202377CD015775
     [Google Scholar]
/content/journals/covid/10.2174/0126667975274661240614051821
Loading
The Effect of Plasma Exchange on Recovery of Patients with Coronavirus Disease 2019 (COVID-19) Admitted to the Intensive Care Unit
Coronaviruses 6, E240624231249 (2025); https://doi.org/10.2174/0126667975274661240614051821
/content/journals/covid/10.2174/0126667975274661240614051821
/content/journals/covid/10.2174/0126667975274661240614051821
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): COVID-19; oxygen saturation; pandemic; plasma exchange; pneumonia; SARS-CoV-2

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test